2,500% Returns? This Stock Is Like Buying Illumina in 2007
Biotech company 10x Genomics (NASDAQ: TXG) manufactures equipment that helps researchers better analyze how a single cell functions and interacts with another single cell. Think of the company's technology like gracefully peeling back the layers of an onion, one layer at a time -- a big improvement over previous processes, in which scientists essentially had to smash the "onion" against a wall to see what was inside.
The level of elegant detail and in-depth characterization allowed by 10x Genomics's technology had not been available before, and early investors have been well rewarded -- the company's stock price has already tripled since its September 2019 IPO. But there could be much more to come.
Scientists worldwide are drooling over the company's technology; its equipment is in use by all 100 of the top global research institutions and all 20 of the top global pharmaceutical companies, with over 2,400 of its instruments in play overall. Not only that, but its products have been mentioned in more than 2,250 research papers across multiple fields of scientific research. Bottom line, the company's razor-and-blade equipment model has quickly become deeply woven into the scientific community. A company hasn't taken the industry by storm like this since Illumina's (NASDAQ: ILMN) DNA sequencing platforms in the early 2000s.
Source Fool.com
